Format

Send to

Choose Destination
See comment in PubMed Commons below
Methods Mol Med. 2006;127:363-74.

Assuring the quality, safety, and efficacy of DNA vaccines.

Author information

1
National Institute for Biological Standards and Control, Herts, UK.

Abstract

Scientists in academia whose research is aimed at the development of a novel vaccine or approach to vaccination may not always be fully aware of the regulatory process by which a candidate vaccine becomes a licensed product. It is useful for such scientists to be aware of these processes, as the development of a novel vaccine could be problematic as a result of the starting material often being developed in a research laboratory under ill-defined conditions. This chapter examines the regulatory process with respect to the development of a DNA vaccine. DNA vaccines present unusual safety considerations which must be addressed during nonclinical safety studies, including adverse immunopathology, genotoxicity through integration into a vaccinee's chromosomes and the potential for the formation of anti-DNA antibodies.

PMID:
16988466
DOI:
10.1385/1-59745-168-1:363
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center